These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26788583)

  • 1. Comparative advantages of new drugs: French Pharmacoeconomic Committee is not sufficiently demanding.
    Prescrire Int; 2015 Dec; 24(166):303-7. PubMed ID: 26788583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards better patient care: drugs to avoid in 2016.
    Prescrire Int; 2016 Apr; 25(170):105-11. PubMed ID: 27186626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Access to medicines in France].
    Bouvenot G; Bouvenot J
    Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of drug efficacy].
    Massol J; Le Jeunne C
    Presse Med; 2007 Mar; 36(3 Pt 2):505-11. PubMed ID: 17270386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Generic drugs in the medical-economic context of drug prescriptions].
    Bouvenot G; Villani P; Bouvenot J
    Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
    Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
    Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.